%0 Journal Article
%T Active A¦Â immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
%A Ana Graf
%A Angelika Caputo
%A Giovanni Marotta
%A J. Michael Ryan
%A Judit Sovago
%A Marie-Emmanuelle Riviere
%A Martin Farlow
%A Philip Scheltens
%A R. Paul Maguire
%A Raquel Sanchez-Valle
%J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions".
%D 2017
%R 10.1016/j.trci.2016.12.003
%X This randomized, double-blind, placebo-controlled, 90-week study assessed safety, tolerability, and immunogenicity of CAD106 with/without adjuvant in patients with mild Alzheimer's disease
%K Alzheimer's disease
%K CAD106
%K Active immunotherapy
%K Amyloid-beta peptides
%K Safety
%K Biological biomarkers
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651373/